Historically, HER2-mutated lung cancer was treated with cytotoxic chemotherapy, unlike other oncogene-driven cancers that used targeted therapies upfront. Zongertinib's approval as a first-line oral TKI marks a significant philosophical shift, aligning its treatment strategy with the biomarker-driven care standard in lung oncology.

Despite both being options, experts favor the TKI zongertinib for second-line treatment of HER2-mutant NSCLC. This preference is driven by zongertinib's higher response rates (~71%) and longer progression-free survival in this setting, coupled with a better side effect profile compared to the ADC trastuzumab-deruxtecan (TDXD).

Despite both Zongertinib and Sevabirtinib showing high efficacy in HER2-mutant NSCLC, Zongertinib's selective nature results in a much better safety profile. Sevabirtinib's dual EGFR/HER2 inhibition leads to significant GI and skin toxicities, making tolerability, not just efficacy, the key factor for clinical preference.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

For HER2-mutant NSCLC, Zongertinib (a TKI) is now the first-line choice. While TKIs show activity after ADCs like TDXD, the effectiveness of using an ADC after TKI failure remains an unproven but critical clinical question for oncologists.

Due to high unmet medical need in non-muscle invasive bladder cancer, the FDA created a special regulatory pathway. This guidance allows for full marketing approval based on a single-arm, open-label study of just 100 patients, dramatically accelerating the timeline and reducing the cost to bring new therapies to market.

The new treatment paradigm for HER2-positive lung cancer will likely involve sequencing a TKI like zongertinib first, followed by an antibody-drug conjugate (ADC). Early data suggests that the efficacy of TKIs is significantly reduced when used after an ADC, making the TKI-first approach critical for maximizing patient outcomes.

Zongertinib shows a meaningful intracranial response rate of ~44% in HER2-mutant NSCLC. This efficacy supports initiating systemic TKI therapy for patients with small, asymptomatic brain metastases and monitoring closely with short-interval scans, potentially avoiding or delaying brain radiation and its associated toxicities.

Clinicians are pragmatically using novel drug combinations based on safety and early efficacy data from Phase 1b/2 trials like ELEVATE. This practice circumvents the impossibility of running Phase 3 trials for every permutation and is reportedly being covered by insurers, accelerating patient access to new options.